Latest News

  • Fat fuels the road to cancer cell spread
    Cancer cells spread to other sites in the body through promoting the growth of new ‘roads’ to travel on. In a study to be published on December 26th in the top scientific journal, Nature, an international and multidisciplinary team of researchers, led by Prof. Dr. Peter Carmeliet (VIB-KU Leuven), discovered how a shift to increased fat utilization is required for the development and growth of these ‘roads’, termed lymphatic vessels – a special kind of blood vessels. This discovery paves the way towards developing therapeutics to limit lymphatic vessel growth in cancer by targeting fat utilization.
  • New point of attack against stomach bacterium Helicobacter pylori
    Neutrons help to determine important enzyme functionThere is a strong suspicion that Helicobacter pylori is linked to the development of stomach cancer. Now an international team of researchers led by Prof. Donald R. Ronning (University of Toledo, USA) has used neutrons to unlock the secret to the functionality of an important enzyme in the bacterium's metabolism. This could be used as a point of attack for new medications. The team made the corresponding measurements at the neutron sources in Oak Ridge (USA) and at the research neutron source reactor FRM II of the Technical University of Munich (TUM).
  • The Party Pooper’s Christmas Carol
    In what has become a tradition cheesier than a vintage Stilton, NHS Digital (UK) shows you that the festive season can have its perils…
  • AstraZeneca and Lilly to develop second potentially disease-modifying treatment for Alzheimer’s Disease
    AstraZeneca and Eli Lilly and Company today announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aß42), which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer’s disease (AD). This agreement builds on the existing collaboration related to AZD3293, a BACE inhibitor in two pivotal Phase III trials.
  • Frequent sauna bathing protects men against dementia
    Frequent sauna bathing can reduce the risk of dementia, according to a recent study carried out at the University of Eastern Finland. In a 20-year follow-up, men taking a sauna 4–7 times a week were 66% less likely to be diagnosed with dementia than those taking a sauna once a week. The association between sauna bathing and dementia risk has not been previously investigated.
view more

Podcasts

view more

Webinars

  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more

Features

view more

Downloads

view more

25 Hottest Articles

view more